BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35709886)

  • 41. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
    Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
    Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models.
    Iba M; Kim C; Florio J; Mante M; Adame A; Rockenstein E; Kwon S; Rissman R; Masliah E
    Front Neurosci; 2020; 14():286. PubMed ID: 32296304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD.
    Iba M; McDevitt RA; Kim C; Roy R; Sarantopoulou D; Tommer E; Siegars B; Sallin M; Kwon S; Sen JM; Sen R; Masliah E
    Mol Neurodegener; 2022 Sep; 17(1):60. PubMed ID: 36064424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson's disease.
    Schechter M; Grigoletto J; Abd-Elhadi S; Glickstein H; Friedman A; Serrano GE; Beach TG; Sharon R
    Mol Neurodegener; 2020 Mar; 15(1):24. PubMed ID: 32228705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
    Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
    Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring α-synuclein aggregation.
    Estaun-Panzano J; Arotcarena ML; Bezard E
    Neurobiol Dis; 2023 Jan; 176():105966. PubMed ID: 36527982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
    Miao Y; Meng H
    Cell Commun Signal; 2024 Jan; 22(1):31. PubMed ID: 38216911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
    Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
    J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice.
    Gu H; Yang X; Mao X; Xu E; Qi C; Wang H; Brahmachari S; York B; Sriparna M; Li A; Chang M; Patel P; Dawson VL; Dawson TM
    Front Cell Neurosci; 2021; 15():656426. PubMed ID: 33776654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation.
    Diógenes MJ; Dias RB; Rombo DM; Vicente Miranda H; Maiolino F; Guerreiro P; Näsström T; Franquelim HG; Oliveira LM; Castanho MA; Lannfelt L; Bergström J; Ingelsson M; Quintas A; Sebastião AM; Lopes LV; Outeiro TF
    J Neurosci; 2012 Aug; 32(34):11750-62. PubMed ID: 22915117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
    Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
    Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Astrocyte glutamate transporters are increased in an early sporadic model of synucleinopathy.
    Diniz LP; Araujo APB; Matias I; Garcia MN; Barros-Aragão FGQ; de Melo Reis RA; Foguel D; Braga C; Figueiredo CP; Romão L; Gomes FCA
    Neurochem Int; 2020 Sep; 138():104758. PubMed ID: 32439533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical Detection of Alpha-Synuclein Seeding Activity in the Colon of a Transgenic Mouse Model of Synucleinopathy by RT-QuIC.
    Han JY; Shin C; Choi YP
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33926043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
    El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
    Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
    J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.